Ramón Azanza, JoséMensa, JoséBarberán, JoséVázquez, LourdesPérez de Oteyza, JaimeKwon, MiYáñez, LucreciaAguado, José MaríaCubillo Gracian, AntonioSolano, CarlosRuiz Camps, IsabelFortún, JesúsSalavert Lletí, MiguelGudiol, CarlotaOlave Rubio, TeresaGarcia Vidal, CarolinaRovira Tarrats, MontserratSuárez-Lledó Grande, MaríaGonzález Sierra, PedroDueñas Gutiérrez, Carlos2025-12-032025-12-032023-04-010214-3429https://hdl.handle.net/2445/224642The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the administration of some drugs in the azole group, which include voriconazole, posaconazole and isavuconazole, noted for their activity against these pathogens. One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, or any of the vinca alkaloids, are very clear examples of risk, in some cases because their clearance is reduced and in others because of increased risk of QTc prolongation, which is particularly evident when the drug of choice is voriconazole or posaconazole.23 p.application/pdfengcc-by-nc (c) Ramón Azanza, José et al., 2023https://creativecommons.org/licenses/by-nc/4.0/Malalties hematològiquesEfecte dels medicaments sobre els microorganismesMedicaments antifúngicsHematologic diseasesEffect of drugs on microorganismsAntifungal agentsinfo:eu-repo/semantics/article2025-12-03info:eu-repo/semantics/openAccess37017117